Editas Medicine, Inc. (EDIT)

Editas Medicine Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	32.31	78.12	19.71	25.54	90.73
Revenue Growth (YoY)	-58.64%	296.32%	-22.83%	-71.85%	341.93%
Cost of Revenue	199.25	177.65	174.96	142.51	158
Gross Profit	-166.93	-99.53	-155.25	-116.96	-67.26
Selling, General & Admin	71.99	69.65	70.7	76.18	67.58
Operating Expenses	71.99	69.65	70.7	76.18	67.58
Operating Income	-238.92	-169.18	-225.95	-193.15	-134.84
Interest & Investment Income	14.06	17.57	5.52	0.61	2.61
Other Non Operating Income (Expenses)	-	-	-	0.04	-0.11
EBT Excluding Unusual Items	-224.86	-151.62	-220.43	-192.5	-132.34
Merger & Restructuring Charges	-12.23	-	-	-	-
Gain (Loss) on Sale of Investments	-0	-1.6	-	-	16.37
Pretax Income	-237.09	-153.22	-220.43	-192.5	-115.98
Net Income	-237.09	-153.22	-220.43	-192.5	-115.98
Net Income to Common	-237.09	-153.22	-220.43	-192.5	-115.98
Shares Outstanding (Basic)	82	76	69	68	59
Shares Outstanding (Diluted)	82	76	69	68	59
Shares Change (YoY)	8.39%	10.63%	1.55%	15.37%	17.26%
EPS (Basic)	-2.88	-2.02	-3.21	-2.85	-1.98
EPS (Diluted)	-2.88	-2.02	-3.21	-2.85	-1.98
Free Cash Flow	-219.11	-136.9	-181.47	-171.78	-187.01
Free Cash Flow Per Share	-2.66	-1.80	-2.64	-2.54	-3.19
Gross Margin	-	-127.40%	-	-	-74.13%
Operating Margin	-739.37%	-216.56%	-1146.26%	-756.13%	-148.61%
Profit Margin	-733.72%	-196.13%	-1118.26%	-753.61%	-127.82%
Free Cash Flow Margin	-678.06%	-175.23%	-920.59%	-672.49%	-206.11%
EBITDA	-233.11	-163.12	-219.61	-188.09	-130.88
EBITDA Margin	-	-208.80%	-	-	-144.25%
D&A For EBITDA	5.81	6.06	6.34	5.05	3.96
EBIT	-238.92	-169.18	-225.95	-193.15	-134.84
EBIT Margin	-	-216.56%	-	-	-148.61%

Updated Mar 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q